[go: up one dir, main page]

WO1990012577A2 - Anti-angiogenique topique a usage d'inhibiteur de croissance capillaire - Google Patents

Anti-angiogenique topique a usage d'inhibiteur de croissance capillaire Download PDF

Info

Publication number
WO1990012577A2
WO1990012577A2 PCT/US1990/000812 US9000812W WO9012577A2 WO 1990012577 A2 WO1990012577 A2 WO 1990012577A2 US 9000812 W US9000812 W US 9000812W WO 9012577 A2 WO9012577 A2 WO 9012577A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
composition
formula
aryl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1990/000812
Other languages
English (en)
Other versions
WO1990012577A3 (fr
Inventor
J. Michael Holland
Duane B. Lakings
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Priority to KR1019900702637A priority Critical patent/KR920700035A/ko
Publication of WO1990012577A2 publication Critical patent/WO1990012577A2/fr
Anticipated expiration legal-status Critical
Publication of WO1990012577A3 publication Critical patent/WO1990012577A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A61Q7/02—Preparations for inhibiting or slowing hair growth

Definitions

  • Angiogenesis is the development of blood vessels which typically would lead to a vascular bed capable of sustaining viable tissue. Angiogenesis is a necessary process in the establishment of embryonic tissue and development of a viable embryo. Similarly angiogenesis is a necessary step in the establishment and development of tumor tissue as well as certain inflammatory conditions. The inhibition of angiogenesis is therefore useful in the control of embryogenesis, inflammatory conditions, and tumor growth, as well as numerous other conditions.
  • R 4 is H, CH 3 , Cl or F

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Cosmetics (AREA)

Abstract

Est décrit un procédé pour inhiber la croissance capillaire chez des mammifères, qui comporte l'administration topique d'une composition renfermant une quantité efficace anti-angiogénique d'un composé angiostatique de formule (I). Ce composé est présent dans une quantité d'au moins 1 mg/ml, de préférence comprise entre environ 1 mg/ml et environ 10 mg/ml.
PCT/US1990/000812 1989-04-18 1990-02-20 Anti-angiogenique topique a usage d'inhibiteur de croissance capillaire Ceased WO1990012577A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019900702637A KR920700035A (ko) 1989-04-18 1990-02-20 털 성장 억제제로서의 국소 항-맥관형성제

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33983689A 1989-04-18 1989-04-18
US339,836 1989-04-18

Publications (2)

Publication Number Publication Date
WO1990012577A2 true WO1990012577A2 (fr) 1990-11-01
WO1990012577A3 WO1990012577A3 (fr) 1992-03-19

Family

ID=23330825

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/000812 Ceased WO1990012577A2 (fr) 1989-04-18 1990-02-20 Anti-angiogenique topique a usage d'inhibiteur de croissance capillaire

Country Status (5)

Country Link
EP (1) EP0468969A1 (fr)
JP (1) JPH04504572A (fr)
KR (1) KR920700035A (fr)
AU (1) AU5154990A (fr)
WO (1) WO1990012577A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026712A3 (fr) * 1995-02-28 1996-11-21 Handelman Joseph H Emploi de suppresseurs d'angiogenese pour inhiber la pousse des poils
US6596703B1 (en) 1997-07-11 2003-07-22 Jagotec Ag Promotion of wound healing utilizing steroids having reduced deteriorous systemic side effects typical of glucocorticoids, mineralocorticoids and sex steroids
EP1726297A1 (fr) * 2005-05-23 2006-11-29 Reckitt Benckiser (UK) LIMITED Composition comprenant de la wortmannine et son utilisation pour inhiber la croissance capillaire
US8334279B2 (en) 2008-05-28 2012-12-18 Validus Genetics Non-hormonal steroid modulators of NF-κB for treatment of disease
US10000525B2 (en) 2010-04-05 2018-06-19 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-κB for treatment of disease
US10799514B2 (en) 2015-06-29 2020-10-13 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2872040B1 (fr) * 2004-06-23 2006-09-22 Centre Nat Rech Scient Cnrse Utilisation cosmetique d'au moins un tetrapeptide naturel ac-n-ser-asp-lys-pro- ou un de ses analogues en tant qu'agent antivieillissement et restructurant de la peau

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Acta Physiol. Latinoam., Volume 28, 1978, (Buenos Aires, AR), A.B. HOUSSAY et al.: "Effects of Halogenated Analogues of Cortisol and Progesterone Upon Hair Growth in Castrated Mice", pages 11-16 *
Arch. of Dermatological Research, Volume 277, No. 1, 1985, Springer-Verlag, (Berlin, DE), S. MAJEWSKI et al.: " Relationship Between the Hair Growth Cycle and the Intensity of Lymphocyte-Induced Angiogenesis in Mouse Skin", pages 77-78 *
Endocrinology, Volume 119, No. 4, 1986, The Endocrine Society, (Baltimore, US), D.E. INGBER et al.: "A Possible Mechanism for Inhibition of Angiogenesis by Angiostatic Steroids: Induction of Capillary Basement Membrane Dissolution", pages 1768-1775 *
Laboratory Investigation, Volume 59, No. 1, 1988, The United States and Canadian Academy of Pathology, Inc., (Washington, US), D. INGBER et al.: "Inhibition of Angiogenesis Through Modulation of Collagen Metabolism", pages 44-51 *
Proceedngs of AACR, Volume 26, March 1985, J. FOLKMAN: "How is Blood Vessel Growth Regulated in Normal and Neoplastic Tissue", pages 384-385 *
The Journal of Investigative Dermatology, Volume 90, No. 3, 198, The Society for Investigative Dermatology, Inc., (Baltimor, US), K.S. STENN eet al.: "The Angiongenic Properties of the Rat Vibrissa Hair Follicle Associate with the Bulb", Pages 409-411 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026712A3 (fr) * 1995-02-28 1996-11-21 Handelman Joseph H Emploi de suppresseurs d'angiogenese pour inhiber la pousse des poils
AU719106B2 (en) * 1995-02-28 2000-05-04 Gillette Company, The Use of angiogenesis suppressors for inhibiting hair growth
US6093748A (en) * 1995-02-28 2000-07-25 Ahluwalia; Gurpreet S. Inhibition of hair growth
US6596703B1 (en) 1997-07-11 2003-07-22 Jagotec Ag Promotion of wound healing utilizing steroids having reduced deteriorous systemic side effects typical of glucocorticoids, mineralocorticoids and sex steroids
EP1726297A1 (fr) * 2005-05-23 2006-11-29 Reckitt Benckiser (UK) LIMITED Composition comprenant de la wortmannine et son utilisation pour inhiber la croissance capillaire
WO2006125979A1 (fr) * 2005-05-23 2006-11-30 Reckitt Benckiser (Uk) Limited Composition comprenant de la wortmannine et son utilisation topique dans la reduction de la pilosite chez l’homme
US9434758B2 (en) 2008-05-28 2016-09-06 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-κB for treatment of disease
US8673887B2 (en) 2008-05-28 2014-03-18 Reveragen Biopharma, Inc Non-hormonal steroid modulators of NF-kB for treatment of disease
US8334279B2 (en) 2008-05-28 2012-12-18 Validus Genetics Non-hormonal steroid modulators of NF-κB for treatment of disease
US9649320B2 (en) 2008-05-28 2017-05-16 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-κB for treatment of disease
US10206933B2 (en) 2008-05-28 2019-02-19 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kB for treatment of disease
US10857161B2 (en) 2008-05-28 2020-12-08 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kB for treatment of disease
US11833159B2 (en) 2008-05-28 2023-12-05 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kB for treatment of disease
US10000525B2 (en) 2010-04-05 2018-06-19 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-κB for treatment of disease
US10799514B2 (en) 2015-06-29 2020-10-13 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions
US11471471B2 (en) 2019-03-07 2022-10-18 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions
US12201639B2 (en) 2019-03-07 2025-01-21 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions

Also Published As

Publication number Publication date
AU5154990A (en) 1990-11-16
KR920700035A (ko) 1992-02-19
WO1990012577A3 (fr) 1992-03-19
EP0468969A1 (fr) 1992-02-05
JPH04504572A (ja) 1992-08-13

Similar Documents

Publication Publication Date Title
US4743597A (en) Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases
EP0189738B1 (fr) Compositions topiques pour la prévention ou le traitement de dessèchement cutané
EP1653974B1 (fr) Amelioration de l'activite et/ou de la duree d'action de steroides anti-inflammatoires doux pour une application topique ou locale
EP0551321A1 (fr) Compositions contenant des derives de steroides
PL118567B1 (en) Process for preparing novel esters of 4-halogen-3-ketoandrosteno-4-carbo-17 betha-thiolic acidosteno-4-karbotiolovojj-17 kisloty
US5258391A (en) Phenyl alpha acyloxyalkanoic acids, derivatives and their therapeutic use
Munro et al. Clobetasone butyrate, a new topical corticosteroid: clinical activity and effects on pituitary-adrenal axis function and model of epidermal atrophy.
WO1990012577A2 (fr) Anti-angiogenique topique a usage d'inhibiteur de croissance capillaire
Giannotti et al. Topical corticosteroids: which drug and when?
JP3504279B2 (ja) 皮膚の萎縮軽減剤、およびその使用法
PL190023B1 (pl) Zastosowanie mieszaniny diolu i alfa-hydroksykwasu do wytwarzani leku do leczenia hiperkeratozowychchorób skóry
KR20010071319A (ko) 미녹시딜 함유 외용 조성물
US3966924A (en) Composition and method for treating psoriasis
JP2004501195A (ja) 神経保護７−β−ヒドロキシステロイド
US6541517B1 (en) Treatment of skin disorders
JP2788739B2 (ja) にきびまたはアンドロゲン性脱毛の局所治療のためのエチステロンの使用
KR100249555B1 (ko) 스테로이드를 함유하는 안구용 조성물, 및 녹내장 치료에 이들 조성물을 사용하는 방법
JPH01203327A (ja) ピリミジン誘導体およびフツ化ステロイド抗炎症済の組み合わせ
McDONALD et al. Hydrocortisone (compound F) in ophthalmology: Clinical and experimental studies
DE602004008083T2 (de) Verstärkung der aktivität und/oder wirkdauer von ausgewählten entzündungshemmenden steroiden
JPH08208487A (ja) 炎症性皮膚疾患治療用外用剤
Loder et al. Halobetasol propionate
JPH08259465A (ja) 皮膚疾患治療用外用剤
KR950032229A (ko) 코르티코이드 유도체와 약학적 및 화장품용 조성물
US3320127A (en) 21-desoxy-9-alpha-fluoro-6-methylprednisolone dermatological compositions

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1990903703

Country of ref document: EP

AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR CA FI HU JP KP KR LK MC MG MW NO RO SD SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB IT LU ML MR NL SE SN TD TG

WWP Wipo information: published in national office

Ref document number: 1990903703

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BB BG BR CA FI HU JP KP KR LK MC MG MW NO RO SD SU US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB IT LU ML MR NL SE SN TD TG

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1990903703

Country of ref document: EP